Sirera Guillem, Videla Sebastià, López-Blázquez Raquel, Llatjos Mariona, Tarrats Antoni, Castellà Eva, Grane Nuria, Tural Cristina, Rey-Joly Celestino, Clotet Bonaventura
HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona (U.A.B.), Badalona, Barcelona, Spain.
J Antimicrob Chemother. 2008 Jan;61(1):191-4. doi: 10.1093/jac/dkm412. Epub 2007 Oct 31.
To provide evidence for the long-term effect of highly active antiretroviral therapy (HAART) on the incidence of cervical squamous intraepithelial lesions (SILs) among HIV-positive women with normal cytology test and CD4 count above 350 cells/mm(3).
A retrospective cohort study was carried out in HIV-positive women with two consecutive normal cervical cytological tests (Papanicolaou test) and at least one subsequent test, without previous cervical history of SIL or cancer diagnosis, and with an immunological status >350 CD4 cells/mm(3). The patients were divided into two groups: treated with HAART (HAART group) or not treated with HAART (NO-HAART group), during the period of time between cytology tests included in the survival analysis and time until SIL.
Between January 1997 and December 2006, 127 women were included: 90 in the HAART group and 37 in the NO-HAART group. Both groups of patients were similar with respect to demographic data, except for HIV viral load and previous HAART inclusion (P < 0.001). SIL was diagnosed in 27 of 90 (30%) patients in the HAART group and in 7 of 37 (19%) patients in the NO-HAART group (OR = 1.84, 95% CI: 0.72-4.69, P = 0.202). The actuarial probability of remaining free of SIL at 3 years was 70% in the HAART group and 78% in the NO-HAART group. No variable was associated with an increased risk of developing SILs.
These results suggest that when the patients' immunological status is above 350 CD4 cells/mm(3), the HIV-infected women treated with HAART present a similar cervical SIL incidence to women not on HAART.
为高效抗逆转录病毒治疗(HAART)对细胞学检查正常且CD4细胞计数高于350个/mm³的HIV阳性女性宫颈鳞状上皮内病变(SILs)发生率的长期影响提供证据。
对连续两次宫颈细胞学检查(巴氏涂片)结果正常、至少有一次后续检查、既往无SIL病史或癌症诊断且免疫状态>350个CD4细胞/mm³的HIV阳性女性进行回顾性队列研究。在生存分析中纳入的细胞学检查之间的时间段以及直至发生SIL的时间内,将患者分为两组:接受HAART治疗组(HAART组)和未接受HAART治疗组(非HAART组)。
1997年1月至2006年12月,共纳入127名女性:HAART组90名,非HAART组37名。除HIV病毒载量和既往是否纳入HAART治疗外,两组患者的人口统计学数据相似(P<0.001)。HAART组90名患者中有27名(30%)被诊断为SIL,非HAART组37名患者中有7名(19%)被诊断为SIL(比值比=1.84,95%置信区间:0.72 - 4.69,P = 0.202)。HAART组3年时无SIL的精算概率为70%,非HAART组为78%。没有变量与发生SIL的风险增加相关。
这些结果表明,当患者免疫状态高于350个CD4细胞/mm³时,接受HAART治疗的HIV感染女性的宫颈SIL发生率与未接受HAART治疗的女性相似。